Hostname: page-component-8448b6f56d-m8qmq Total loading time: 0 Render date: 2024-04-20T02:01:48.107Z Has data issue: false hasContentIssue false

P.139 Cerebral toxoplasmosis in an HIV-negative patient

Published online by Cambridge University Press:  05 June 2023

E Liu
Affiliation:
(Saskatoon)*
P Kakodkar
Affiliation:
(Saskatoon)
P Toyota
Affiliation:
(Saskatoon)
N Pendleton
Affiliation:
(Saskatoon)
A Persad
Affiliation:
(Saskatoon)
V Zherebitskiy
Affiliation:
(Saskatoon)
C Hamula
Affiliation:
(Saskatoon)
RN Auer
Affiliation:
(Saskatoon)
K Vats
Affiliation:
(Saskatoon)
L Hnenny
Affiliation:
(Saskatoon)
J Radic
Affiliation:
(Saskatoon)
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Background: Toxoplasma gondii is a protozoan parasite with the ability to infect any nucleated cell in humans. Most immunocompetent infected individuals are asymptomatic. Latent toxoplasma can become reactivated in immunocompromised individuals though this is exceptionally rare in HIV-negative individuals. Methods: We present the case of a 47-year-old male with chronic immunosuppression secondary to marginal zone lymphoma and steroid therapy. Results: The patient presented to hospital with a 1-week history of word-finding difficulties, intermittent right facial numbness and leg weakness, and tonic-clonic seizures. CT head showed a left temporal heterogenous mass measuring 2.8 × 2.8 × 3.5 cm. Biopsy of the lesion showed Multiple tachyzoites and rare bradyzoites with strong positivity for the toxoplasma specific immunostain. The patient was treated with trimethoprim/sulfamethoxazole which resulted in complete neurologic recovery. Conclusions: Our literature review included 32 cases of cerebral toxoplasmosis in HIV-negative patients with an overall mortality rate of 48%. Cerebral toxoplasmosis has a predilection for immunosuppressed patients with an underlying hematologic malignancy (74%, n= 23). Successful treatment requires early recognition of the disease and prompt treatment with sulfamethoxazole and trimethoprim, pyrimethamine, or sulfadiazine. Patients who recover from acute toxoplasmosis should remain on lifelong suppressive antibiotic therapy to prevent relapse.

Type
Abstracts
Copyright
© The Author(s), 2023. Published by Cambridge University Press on behalf of Canadian Neurological Sciences Federation